Supportive Care in Cancer

, Volume 12, Issue 2, pp 80–85 | Cite as

Specific infectious complications after stem cell transplantation

  • Holger HebartEmail author
  • Hermann Einsele
Review Article


Infectious complications continue to be a leading cause of morbidity and mortality after stem cell transplantation (SCT). The most important determinants for risk and outcomes are the stem cell source and the time after transplantation that the infection occurs. More recent developments in preparative regimens and graft manipulations, as well as the control of some important infectious complications after SCT by the introduction of effective prophylaxis and preemptive treatment strategies, have had a great impact on the timing and the epidemiology of infections posttransplantation. Better control of infectious complications posttransplantation has resulted in a reduced transplant-related mortality.


Stem cell transplantation Epidemiology Treatment Infectious complication 


  1. 1.
    Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA (2003) Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97:1025–1032CrossRefPubMedGoogle Scholar
  2. 2.
    Boeck M, Bowden RA, Gooley T, Myerson D, Corey L (1999) Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 93:1781–1782PubMedGoogle Scholar
  3. 3.
    Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Benaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86:3598–3603PubMedGoogle Scholar
  4. 4.
    Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE, Moss PAH, Milligan DW (2002) Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100:1619–1627CrossRefPubMedGoogle Scholar
  5. 5.
    Chakraverty R, Robinson S, Peggs K, Kottaridis PD, Watts MJ, Ings SJ, Hale G, Waldmann H, Linch DC, Goldstone AH, Mackinnon S (2001) Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant 28:827–834CrossRefPubMedGoogle Scholar
  6. 6.
    Crippa F, Holmberg L, Carter RA, Hooper H, Marr KA, Bensinger W, Chauncey T, Corey L, Boeck M (2002) Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 8:281–289PubMedGoogle Scholar
  7. 7.
    Einsele H, Ehninger G, Hebart H, Schuler U, Mackes P, Hertter M, Klingebiel T, Löffler J, Wagner S, Müller CA, Boeck M (1995) Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86:2815–2820PubMedGoogle Scholar
  8. 8.
    Einsele H, Hebart H, Roller G, Löffler J, Rothenhöfer I, Müller CA, Bowden RA, van-Burik J, Engelhard D, Kanz L, Schumacher U (1997) Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 35:1353–1360PubMedGoogle Scholar
  9. 9.
    Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916–3922CrossRefPubMedGoogle Scholar
  10. 10.
    Gärtner BC, Schäfer H, Marggraff K, Eisele G, Schafer M, Dilloo D, Roemer K, Laws HJ, Sester M, Sester U, Einsele H, Mueller-Lantzsch N (2002) Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 40:351–358PubMedGoogle Scholar
  11. 11.
    Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95:807–814Google Scholar
  12. 12.
    Hebart H, Löffler J, Meisner C, Serey F, Schmidt D, Böhme A, Martin H, Engel A, Bunjes D, Kern WV, Schumacher U, Kanz L, Einsele H (2000) Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 181:1713–1719PubMedGoogle Scholar
  13. 13.
    Hebart H, Brugger W, Grigoleit U, Gscheidle B, Loeffler J, Schafer H, Kanz L, Einsele H, Sinzger C (2001) Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 97:2183–2185CrossRefPubMedGoogle Scholar
  14. 14.
    Hebart H, Bollinger C, Fisch P, Sarfati J, Meisner C, Baur M, Loeffler J, Monod M, Latge JP, Einsele H (2002) Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 100:4521–4528CrossRefPubMedGoogle Scholar
  15. 15.
    Hebart H, Daginik S, Stevanovic S, Grigoleit U, Dobler A, Baur M, Rauser G, Sinzger C, Jahn G, Loeffler J, Kanz L, Rammensee HG, Einsele H (2002) Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 99:3830–3837CrossRefPubMedGoogle Scholar
  16. 16.
    Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, Villard O, Liu KL, Natarajan-Amé S, Lutz P, Dufour P, Bergerat JP, Candolfi E (2002) Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 20:1898–1906CrossRefPubMedGoogle Scholar
  17. 17.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Cailolt D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415PubMedGoogle Scholar
  18. 18.
    Heussel CP, Kauczor HU, Heussel GE, Fischer B, Begrich M, Mildenberger P, Thelen M (1999) Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 17:796–805Google Scholar
  19. 19.
    Holmberg L, Boeck M, Hooper H, Leisenring W, Rowley S, Heimfeld S, Press O, Maloney DG, McSweeney P, Corey L, Maziarz RT, Appelbaum FR, Bensinger W (1999) Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94:4029–4035PubMedGoogle Scholar
  20. 20.
    Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRefPubMedGoogle Scholar
  21. 21.
    Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Storb R (2002) Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8:512–520PubMedGoogle Scholar
  22. 22.
    Junghanss C, Boeck M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Little M.T., Corey L, Storb R (2002) Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99:1978–1985CrossRefPubMedGoogle Scholar
  23. 23.
    Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M (2002) Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 186:1297–1306CrossRefPubMedGoogle Scholar
  24. 24.
    Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, Corey L, Boeckh M (2000) Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96:2055–2061PubMedGoogle Scholar
  25. 25.
    Marr KA, Carter RA, Boeck M, Martin PJ, Corey L (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100:4358–4366CrossRefPubMedGoogle Scholar
  26. 26.
    Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909–917PubMedGoogle Scholar
  27. 27.
    Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Press O (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029CrossRefPubMedGoogle Scholar
  28. 28.
    Nichols WG, Price TH, Gooley T, Corey L, Boeckh M (2003) Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 101:4195–4200CrossRefPubMedGoogle Scholar
  29. 29.
    van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ (2002) Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99:4364–4369CrossRefPubMedGoogle Scholar
  30. 30.
    Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg IS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764–771PubMedGoogle Scholar
  31. 31.
    Walter E, Bowden RA (1995) Infection in the bone marrow transplant recipient. Infect Dis Clin North Am 9:823–847PubMedGoogle Scholar
  32. 32.
    Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038–1044CrossRefPubMedGoogle Scholar
  33. 33.
    Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JN, Raad I, Przepiorka D, Lewis VA, Mirza N, Yousuf H, Tarrand JJ, Bodey GP (1996) Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 22:778–782PubMedGoogle Scholar
  34. 34.
    Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM (1988) Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520–529PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Department of Hematology and OncologyUniversity of TübingenGermany
  2. 2.Abt. Hämatologie OnkologieMedizinische Klinik IITübingenGermany

Personalised recommendations